Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05206370 · ClinicalTrials.gov registry record · Phase 3
A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers
A Phase 3 study, sponsored by Achieve Life Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 792
- Enrollment target
NCT05206370 is a Phase 3 study that has completed, run by Achieve Life Sciences. The registered enrollment target is 792 participants.
The verdict
NCT05206370, a Phase 3 study, has completed, sponsored by Achieve Life Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 792 participants
- Enrollment target
Study Summary
This placebo-controlled Phase 3 study is being conducted at sites within the United States to evaluate 3 mg cytisinicline TID for treatment duration of 42 days/6 weeks and evaluate 3 mg cytisinicline TID for treatment duration of 84 days/12 weeks.
Interventions
- DRUG Placebo
- DRUG Cytisinicline
- BEHAVIORAL Behavioral support
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 792 participants |
| Start Date | 2022-01-20 |
| Est. Completion | 2023-03-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05206370
The ClinicalTrials.gov registry entry for NCT05206370 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 792 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Achieve Life Sciences, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05206370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05206370 about?
NCT05206370 is a clinical study titled "A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers". This placebo-controlled Phase 3 study is being conducted at sites within the United States to evaluate 3 mg cytisinicline TID for treatment duration of 42 days/6 weeks and evaluate 3 mg cytisinicline TID for treatment duration of 84 days/12 weeks.
What is the current status of trial NCT05206370?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 792 participants. The study started on 2022-01-20. Estimated completion is 2023-03-21.
What interventions are being tested in trial NCT05206370?
The interventions under investigation include: Placebo (DRUG), Cytisinicline (DRUG), Behavioral support (BEHAVIORAL).
Who is sponsoring clinical trial NCT05206370?
This trial is sponsored by Achieve Life Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.